Major carcinogenic factors of NSCLC are epidermal growth factor receptor (EGFR) activating mutations, which can be effectively treated with EGFR tyrosine kinase inhibitors (TKIs) [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.